P A Marks is a scholar working on Molecular Biology, Physiology and Genetics.
According to data from OpenAlex, P A Marks has authored 67 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 15 papers in Physiology and 11 papers in Genetics. Recurrent topics in P A Marks's work include Erythrocyte Function and Pathophysiology (13 papers), Histone Deacetylase Inhibitors Research (11 papers) and Hemoglobinopathies and Related Disorders (11 papers). P A Marks is often cited by papers focused on Erythrocyte Function and Pathophysiology (13 papers), Histone Deacetylase Inhibitors Research (11 papers) and Hemoglobinopathies and Related Disorders (11 papers). P A Marks collaborates with scholars based in United States, Canada and United Kingdom. P A Marks's co-authors include Richard A. Rifkind, Victoria M. Richon, Raphael B. Parmigiani, Weisheng Xu, Lang Ngo, R A Rifkind, Weili Xu, A Bank, C. Gui and M Terada and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.
In The Last Decade
P A Marks
67 papers
receiving
8.3k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Histone deacetylase inhibitors: molecular mechanisms of action
20071.2k citationsWeisheng Xu, Raphael B. Parmigiani et al.Oncogeneprofile →
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
20001.0k citationsP A Marks, Victoria M. Richon et al.JNCI Journal of the National Cancer Instituteprofile →
Erythroleukemic Differentiation
1978618 citationsP A Marks, Richard A. Rifkindprofile →
Histone deacetylase inhibitors: Potential in cancer therapy
2009588 citationsP A Marks et al.Journal of Cellular Biochemistryprofile →
This map shows the geographic impact of P A Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P A Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P A Marks more than expected).
This network shows the impact of papers produced by P A Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P A Marks. The network helps show where P A Marks may publish in the future.
Co-authorship network of co-authors of P A Marks
This figure shows the co-authorship network connecting the top 25 collaborators of P A Marks.
A scholar is included among the top collaborators of P A Marks based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with P A Marks. P A Marks is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Marks, P A, et al.. (2015). BODY COMPOSITION DIFFERENCES BY ASSESSMENT METHODS SUCH AS DEXA, HYDROSTATIC, BIO-IMPEDANCE, AND SKIN FOLD. TopSCHOLAR (Western Kentucky University). 8(3). 39.1 indexed citations
Marks, P A, et al.. (2009). Histone deacetylase inhibitors: Potential in cancer therapy. Journal of Cellular Biochemistry. 107(4). 600–608.588 indexed citations breakdown →
4.
Marks, P A. (2007). Discovery and development of SAHA as an anticancer agent. Oncogene. 26(9). 1351–1356.517 indexed citations breakdown →
5.
Xu, Weisheng, Raphael B. Parmigiani, & P A Marks. (2007). Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 26(37). 5541–5552.1245 indexed citations breakdown →
6.
Marks, P A. (2003). Histone deacetylases. Current Opinion in Pharmacology. 3(4). 344–351.296 indexed citations
7.
Kutko, Martha C., Richard D. Glick, Lisa M. Butler, et al.. (2001). The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.. Adelaide Research & Scholarship (AR&S) (University of Adelaide). 61(9). 3591–4.129 indexed citations
8.
Marks, P A, Victoria M. Richon, & Richard A. Rifkind. (2000). Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells. JNCI Journal of the National Cancer Institute. 92(15). 1210–1216.1010 indexed citations breakdown →
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.